ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Nutrition and Supplements
Peter Langsjoen, MD discusses why we should take Coenzyme Q10
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Vince" data-source="post: 21737" data-attributes="member: 843"><p><a href="http://www.excelmale.com/#" target="_blank">Ophthalmologica.</a> 2005 May-Jun;219(3):154-66.</p><p><strong>Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10.</strong></p><p></p><p><a href="http://www.excelmale.com/pubmed/?term=Feher%20J%5BAuthor%5D&cauthor=true&cauthor_uid=15947501" target="_blank">Feher J</a>, <a href="http://www.excelmale.com/pubmed/?term=Kovacs%20B%5BAuthor%5D&cauthor=true&cauthor_uid=15947501" target="_blank">Kovacs B</a>, <a href="http://www.excelmale.com/pubmed/?term=Kovacs%20I%5BAuthor%5D&cauthor=true&cauthor_uid=15947501" target="_blank">Kovacs I</a>, <a href="http://www.excelmale.com/pubmed/?term=Schveoller%20M%5BAuthor%5D&cauthor=true&cauthor_uid=15947501" target="_blank">Schveoller M</a>, <a href="http://www.excelmale.com/pubmed/?term=Papale%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15947501" target="_blank">Papale A</a>, <a href="http://www.excelmale.com/pubmed/?term=Balacco%20Gabrieli%20C%5BAuthor%5D&cauthor=true&cauthor_uid=15947501" target="_blank">Balacco Gabrieli C</a>.</p><p><strong><a href="http://www.excelmale.com/#" target="_blank">Author information</a></strong></p><p></p><p>Ophthalmic Neuroscience Program, Department of Ophthalmology, University of Rome 'La Sapienza', Rome, Italy. <a href="mailto:j.feher@libero.it">j.feher@libero.it</a></p><p></p><p></p><p><strong>Abstract</strong></p><p></p><p>The aim of this randomized, double-blind, placebo-controlled clinical trial was to determine the efficacy of a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10 (Phototrop) on the visual functions and fundus alterations in early age-related macular degeneration (AMD). One hundred and six patients with a clinical diagnosis of early AMD were randomized to the treated or control groups. The primary efficacy variable was the change in the visual field mean defect (VFMD) from baseline to 12 months of treatment, with secondary efficacy parameters: visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by perimetry, and fundus alterations as evaluated according to the criteria of the International Classification and Grading System for AMD. The mean change in all four parameters of visual functions showed significant improvement in the treated group by the end of the study period. In addition, in the treated group only 1 out of 48 cases (2%) while in the placebo group 9 out of 53 (17%) showed clinically significant (>2.0 dB) worsening in VFMD (p = 0.006, odds ratio: 10.93). Decrease in drusen-covered area of treated eyes was also statistically significant as compared to placebo when either the most affected eyes (p = 0.045) or the less affected eyes (p = 0.017) were considered. These findings strongly suggested that an appropriate combination of compounds which affect mitochondrial lipid metabolism, may improve and subsequently stabilize visual functions, and it may also improve fundus alterations in patients affected by early AMD.</p><p><a href="http://www.ncbi.nlm.nih.gov/pubmed/15947501" target="_blank">http://www.ncbi.nlm.nih.gov/pubmed/15947501</a></p></blockquote><p></p>
[QUOTE="Vince, post: 21737, member: 843"] [URL="http://www.excelmale.com/#"]Ophthalmologica.[/URL] 2005 May-Jun;219(3):154-66. [B]Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10.[/B] [URL="http://www.excelmale.com/pubmed/?term=Feher%20J%5BAuthor%5D&cauthor=true&cauthor_uid=15947501"]Feher J[/URL], [URL="http://www.excelmale.com/pubmed/?term=Kovacs%20B%5BAuthor%5D&cauthor=true&cauthor_uid=15947501"]Kovacs B[/URL], [URL="http://www.excelmale.com/pubmed/?term=Kovacs%20I%5BAuthor%5D&cauthor=true&cauthor_uid=15947501"]Kovacs I[/URL], [URL="http://www.excelmale.com/pubmed/?term=Schveoller%20M%5BAuthor%5D&cauthor=true&cauthor_uid=15947501"]Schveoller M[/URL], [URL="http://www.excelmale.com/pubmed/?term=Papale%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15947501"]Papale A[/URL], [URL="http://www.excelmale.com/pubmed/?term=Balacco%20Gabrieli%20C%5BAuthor%5D&cauthor=true&cauthor_uid=15947501"]Balacco Gabrieli C[/URL]. [B][URL="http://www.excelmale.com/#"]Author information[/URL][/B] Ophthalmic Neuroscience Program, Department of Ophthalmology, University of Rome 'La Sapienza', Rome, Italy. [EMAIL="j.feher@libero.it"]j.feher@libero.it[/EMAIL] [B]Abstract[/B] The aim of this randomized, double-blind, placebo-controlled clinical trial was to determine the efficacy of a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10 (Phototrop) on the visual functions and fundus alterations in early age-related macular degeneration (AMD). One hundred and six patients with a clinical diagnosis of early AMD were randomized to the treated or control groups. The primary efficacy variable was the change in the visual field mean defect (VFMD) from baseline to 12 months of treatment, with secondary efficacy parameters: visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by perimetry, and fundus alterations as evaluated according to the criteria of the International Classification and Grading System for AMD. The mean change in all four parameters of visual functions showed significant improvement in the treated group by the end of the study period. In addition, in the treated group only 1 out of 48 cases (2%) while in the placebo group 9 out of 53 (17%) showed clinically significant (>2.0 dB) worsening in VFMD (p = 0.006, odds ratio: 10.93). Decrease in drusen-covered area of treated eyes was also statistically significant as compared to placebo when either the most affected eyes (p = 0.045) or the less affected eyes (p = 0.017) were considered. These findings strongly suggested that an appropriate combination of compounds which affect mitochondrial lipid metabolism, may improve and subsequently stabilize visual functions, and it may also improve fundus alterations in patients affected by early AMD. [URL]http://www.ncbi.nlm.nih.gov/pubmed/15947501[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Nutrition and Supplements
Peter Langsjoen, MD discusses why we should take Coenzyme Q10
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top